about
Toxin-based therapeutic approachesIn vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteaseInhibition of human rhinovirus-induced cytokine production by AG7088, a human rhinovirus 3C protease inhibitorIn vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease.Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteersEngineered toxins "zymoxins" are activated by the HCV NS3 protease by removal of an inhibitory protein domain.Removal of hepatitis C virus-infected cells by a zymogenized bacterial toxinProvirus activation plus CD59 blockage triggers antibody-dependent complement-mediated lysis of latently HIV-1-infected cells.Viral capsid mobility: a dynamic conduit for inactivation.Dominant drug targets suppress the emergence of antiviral resistanceHigh-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitorsThe primase domain of PfPrex is a proteolytically matured, essential enzyme of the apicoplast.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer.First generation inhibitors of the adenovirus proteinaseInhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.Tipranavir in the protease inhibitors arena.Research applications of proteolytic enzymes in molecular biology.Sharpening Host Defenses during Infection: Proteases Cut to the Chase.High-throughput screening for the identification of small-molecule inhibitors of the flaviviral protease.Use of fluorescence resonance energy transfer for rapid detection of enteroviral infection in vivo.Hepatitis A virus proteinase 3C binding to viral RNA: correlation with substrate binding and enzyme dimerization.Proteolytic activity assayed by subcellular localization switching of a substrate.Lopinavir inhibits insulin signaling by promoting protein tyrosine phosphatase 1B expression.Deciphering the targets of retroviral protease inhibitors in Plasmodium berghei
P2860
Q27013664-5D7005D7-84AD-485A-A8AE-9AFB62647D14Q28343611-79E0774D-8744-482B-B96E-3B025DE3D516Q28344143-2115F689-319B-43B4-BB8E-02ECE46E2CFFQ30443266-F7979CCC-A96F-4F1F-B617-F7F98ACFF479Q30448643-A1EA5866-87D4-42D3-A474-67B13AE5A698Q30451184-B5FCD9EE-82CE-46EF-9064-F9C398EF25ACQ33802605-8246B038-38B1-4960-AA46-CB3557F47BB4Q34168690-E585A01A-4DDE-430E-8E7A-CACAFCAFB669Q34218827-C079F6DB-073D-4091-B616-8B836520298AQ34451722-20CC677D-800A-4D6B-83DB-D01242A37E4EQ34729490-44C7AEB1-6E53-44AC-9C13-93D42FE87553Q34987358-20E1BD55-A115-4F34-89B1-3541299EF5F6Q35386908-ABED81A1-888A-40C0-B3E7-238BB1833B71Q35567828-0205BA93-CBE8-478B-BACE-3C04B605A9A2Q37029615-18D64EDC-53FF-47C5-A5DB-D65473020CCEQ37072075-AF1CB84E-ED36-4007-85E5-026EDDADAE3BQ37262441-085CBDB8-5C80-4BB4-9186-F4B123A6B90AQ37593477-BD3C378A-97E7-4B76-AD19-2E8DE83115E5Q37963591-666EFFD9-06AD-46FA-8661-429594ECC660Q38223683-2D77517D-E065-4E3D-A137-FC5934243C49Q39127087-7165B637-CCDE-489C-995E-7E4DF24C874DQ40092052-58DEDCC0-0DDD-4F53-BC48-6D897D519963Q40284120-9F5C9AA4-230C-4735-96A3-AE7211D94250Q40516783-E31F0659-0FAC-4D3C-AC96-9F432C7A9F50Q41682829-23A719C4-C235-482B-A90A-1A2A16CAC2C1Q42289070-0C1091DD-87D6-4B66-88D5-F75EE8175878Q56353634-BFEB6511-D226-4740-982F-FE250E435827
P2860
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Protease inhibitors as antiviral agents.
@en
Protease inhibitors as antiviral agents.
@nl
type
label
Protease inhibitors as antiviral agents.
@en
Protease inhibitors as antiviral agents.
@nl
prefLabel
Protease inhibitors as antiviral agents.
@en
Protease inhibitors as antiviral agents.
@nl
P2860
P356
P1476
Protease inhibitors as antiviral agents
@en
P2093
P2860
P304
P356
10.1128/CMR.11.4.614
P407
P577
1998-10-01T00:00:00Z